Praxis Precision Medicines
Clinical trials sponsored by Praxis Precision Medicines, explained in plain language.
-
New hope for babies with rare seizure disorder: drug trial targets SCN2A gene
Disease control Recruiting nowThis study tests a medicine called elsunersen in 40 children with a rare, severe form of epilepsy caused by changes in the SCN2A gene. The goal is to see if the drug can safely reduce how often seizures happen over 24 weeks. Children must have started having seizures before 3 mon…
Phase: PHASE3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for kids with rare epilepsy: drug trial targets seizure control
Disease control Recruiting nowThis study tests an investigational drug called relutrigine in 160 children with a severe form of epilepsy called developmental and epileptic encephalopathy (DEE). The goal is to see if the drug can safely reduce monthly seizure frequency compared to a placebo. After the initial …
Phase: PHASE3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New epilepsy drug vormatrigine enters final testing phase
Disease control Recruiting nowThis Phase 3 trial is testing whether the experimental drug vormatrigine can reduce the frequency of focal seizures in adults with epilepsy. About 300 participants who already take 1 to 3 seizure medications will receive either a low, medium, or high dose of vormatrigine or a pla…
Phase: PHASE3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC